eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention...
schneider said that he is hoping to conduct a subsequent study of 15 to 20 pregnancies and that he is encouraged by these results.., although most have plans that will adequately improve air quality..